Maintaining equity and reducing risk when prescribing valproate: we still have a way to go
Share this article
Click the icon of the social media platform on which you would like to share this article.
Email this article to a friend
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Other content recommended for you
- Antiepileptic drug treatment of rolandic epilepsy and Panayiotopoulos syndrome: clinical practice survey and clinical trial feasibility
- Weighing the risks of valproate in women who could become pregnant
- When the first antiepileptic drug fails in a patient with juvenile myoclonic epilepsy
- New drugs for the treatment of epilepsy: a practical approach
- Valproate and risk of fracture in Rett syndrome
- Epilepsy and pregnancy: identifying risks
- THE BARE ESSENTIALS: Epilepsy
- Valproate and childbearing potential: new regulations
- Typical absence seizures and their treatment
- Impact of regulatory safety notices on valproate prescribing and pregnancy outcome among women of child-bearing potential in Scotland: a population-based cohort study